The prognosis for a thalamic tumor is heavily dependent on its grade, with JPAs (Grade I) having best prognosis. The duration of symptom resolution is somewhat dependent on the grade and growth pattern of the tumor. Bilateral growth that is defined on the MRI and a biopsy proven Grade III or IV tumor are poor prognostic indicators. Today, the molecular features of a tumor that are determined at biopsy play a key role in determining its prognosis and possible treatment options. (See Grading a Glioma.)
Other, more common, childhood cancers once thought to be incurable, such as leukemia, have seen remarkable improvements in survival rates over the past 30 to 40 years, as researchers unlocked their secrets and found effective treatments. Unfortunately there has been limited research into pediatric brain tumors, because it’s so difficult to get funding for it.
Government grants and gifts from major foundations tend to support common cancers, where each advance benefits thousands of people. That makes sense, of course. But how can you tell a parent that not only is there no hope for their child, but that nobody is even working on it? The only way to improve the prognosis for thalamic gliomas and other rare and inoperable brain tumors in children is to study them, get to understand them better, and test innovative therapies for them.
That’s why we’ve launched the Thalamic Glioma Registry — it allows us to collect and study the data so desperately needed to advance the research and improve the odds. (Find out more about the Legacy Donation Program.)
Reviewed by Umberto Tosi, MD
Last reviewed/last updated: September 2024
